European Commercialization of the HAART™ 200 Aortic Annuloplasty Device

BioStable Science & Engineering Initiates European Commercialization of the HAART™ 200 Aortic Annuloplasty Device First commercial implantations of the HAART 200 Device for Bicuspid Aortic Valve repair performed by Professor Marek Jasinski at the Wroclaw Medical University Austin, TX – August 6, 2021 - BioStable Science & Engineering, Inc., announced today that the first commercial implantations of its HAART 200 Aortic Annuloplasty Device were performed on Monday August 2nd by Professor Marek [...]

2021-08-05T21:09:38-05:00August 4th, 2021|Press Release|

CE Mark Approval for the HAART 200 & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices

BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices Austin, TX – April 21, 2021 - BioStable Science & Engineering, Inc., (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and HAART 200 Aortic [...]

2021-04-20T20:21:35-05:00April 20th, 2021|Press Release|

HAART 200 First Commercial Use

BioStable Science & Engineering, Inc. announced today the first commercial use of the HAART 200 Aortic Annuloplasty Device in the U.S. by doctors at the West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia. Drs. Lawrence Wei, Vinay Badhwar and J. Scott Rankin were the collaborating surgeons for the procedure.

2018-12-07T17:37:01-06:00September 26th, 2017|Press Release|
Go to Top